Featured Research

from universities, journals, and other organizations

Mayo Researchers Define Celecoxib Pathways And Mechanisms For Tumor Reduction

Date:
November 15, 2004
Source:
American Association For Cancer Research
Summary:
The anti-inflammatory drug Celebrex, or celecoxib, reduces tumor mass by encouraging cell death and discouraging both cell proliferation and the sprouting of new blood vessels that feed growing tumors, according to a study reported in the November issue of Molecular Cancer Research.

PHILADELPHIA -- The anti-inflammatory drug Celebrex, or celecoxib, reduces tumor mass by encouraging cell death and discouraging both cell proliferation and the sprouting of new blood vessels that feed growing tumors, according to a study reported in the November issue of Molecular Cancer Research.

Related Articles


The study, conducted by researchers at the Mayo Clinic College of Medicine in Scottsdale, Ariz., suggests this drug one day might be used to prevent and even treat breast tumors. Celebrex, marketed by Pfizer Inc., is a member of the general family of drugs that target the COX-2, an enzyme that plays a major role in arthritis pain and inflammation.

"This COX-2 inhibitor represents a strong option for treatment of breast cancers, and a preventative agent for treatment of individuals with high risk of developing breast cancer or disease relapse," said Pinku Mukherjee, Ph.D., the senior author of the report.

The Mayo study showed that celecoxib caused reduction in mammary gland tumor mass that was associated with increased programmed cell death, or apoptosis, in the breast tissue of the mice. Celecoxib-induced cell death was associated with two molecular events involving pathways that lead to apoptosis. The COX-2 inhibitor increased expression of the Bax protein, which is known to function within the pro-apoptotic cell mechanism. Further, the introduction of celecoxib resulted in reduced activity of an anti-apoptotic protein, Akt, known to promote cell survival.

Generally, COX-2 works by regulating the production of prostaglandins in cells. In the Mayo study, celecoxib reduced levels of COX-2 protein in mammary tumor cells; the therapy was even more effective in minimizing the amounts of COX-2 dependent prostaglandin E metabolites in mammary tumor cells.

"Celecoxib treatment appears to exert its antiproliferative, antiangiogenic, and pro-apoptotic effects by regulating the prostaglandin pathways," Mukherjee said. "This leads to the reduction in primary breast tumor mass."

She noted that in an experiment with a limited number of mice, celecoxib appeared to completely inhibit metastasis of the breast tumor.

The study employed a mouse model system that closely resembles spontaneous breast cancer progression and metastasis in humans.

"The MTag mouse model for human metastatic breast cancer is a helpful and important model in which to evaluate therapeutic strategies and to understand the mechanisms associated with therapy-induced growth inhibition," said Mukherjee. "This model allows us to proceed with preclinical studies that must precede clinical trials in order to enable us to develop efficient therapeutic strategies with targeted molecular therapies."

Contributing to this report along with Mukherjee were Mayo Clinic cancer researchers Gargi Basu, Ph.D., the lead author on the paper; as well as Sandra Gendler, Ph.D.; Latha Pathangey; M.S.,Teresa Tinder, B.S.; and Michelle LaGioia.

###

Founded in 1907, the American Association for Cancer Research is a professional society of more than 24,000 laboratory, translational, and clinical scientists engaged in all areas of cancer research in the United States and in more than 60 other countries. AACR's mission is to accelerate the prevention and cure of cancer through research, education, communication, and advocacy. Its principal activities include the publication of five major peer-reviewed scientific journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. AACR's Annual Meetings attract more than 15,000 participants who share new and significant discoveries in the cancer field. Specialty meetings, held throughout the year, focus on the latest developments in all areas of cancer research.


Story Source:

The above story is based on materials provided by American Association For Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association For Cancer Research. "Mayo Researchers Define Celecoxib Pathways And Mechanisms For Tumor Reduction." ScienceDaily. ScienceDaily, 15 November 2004. <www.sciencedaily.com/releases/2004/11/041108021726.htm>.
American Association For Cancer Research. (2004, November 15). Mayo Researchers Define Celecoxib Pathways And Mechanisms For Tumor Reduction. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2004/11/041108021726.htm
American Association For Cancer Research. "Mayo Researchers Define Celecoxib Pathways And Mechanisms For Tumor Reduction." ScienceDaily. www.sciencedaily.com/releases/2004/11/041108021726.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins